Navigation Links
Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100
Date:5/22/2012

NEWTON, Mass., May 22, 2012 /PRNewswire/ -- Halo Therapeutics, LLC, a clinical-stage biopharmaceutical company developing novel therapeutics for rare fibrotic diseases, announced today that it has received financial support totaling $1.1 million from 12 not-for-profit foundations serving the muscular dystrophy patient community. Halo will use the funds to expedite the phase 2 study of HT-100, its lead drug candidate for Duchenne muscular dystrophy (DMD). HT-100, a proprietary formulation of halofuginone, is an orally available small molecule drug candidate being developed to reduce fibrosis and promote healthy muscle fiber regeneration in DMD patients. Halo will begin its phase 2 study in the second half of 2012.

"Companies typically labor for years to attract the level of engagement we have received from such an active, dedicated patient advocacy community," said Marc Blaustein, CEO of Halo Therapeutics. "We are both humbled and heartened by their support and believe that together we are better able to speed the delivery of new therapies for DMD to patients and their families."

DMD is a progressive and fatal neuromuscular disorder, which afflicts approximately 1 in 3,500 boys worldwide. There is currently no treatment. Muscle fibrosis is a primary outcome and ultimately leads to early patient death: Young men with DMD typically live into their twenties or early thirties. In studies, HT-100 has demonstrated potent ability to halt and reverse existing muscle fibrosis as well as promote the growth of healthy new muscle. In an independent review, an international advisory committee of neuromuscular disease experts concluded HT-100 was "ready for the clinic." The drug candidate has received Orphan status in both the U.S. and the EU.

"The community of muscular dystrophy foundations has rallied around our novel and aggressive approach to delivering a promising therapy to DMD boys and their families," said Tom Wicka, founder of the Nash Avery Foundation and father of Nash, age 12. "This level of unification and engagement across the patient advocacy community for an early-stage drug candidate is extremely rare, and we are grateful for the support and vision of our funding partners."

Added Benjamin Seckler, M.D., president of Charley's Fund and father of Charley, age 11: "We have the ultimate drive to get this done quickly: Our children's lives are at stake. We do not have the option of accepting the pace of typical drug development efforts. We thank our foundation partners and value their role in helping us further the development of HT-100 as rapidly as possible."

The foundations providing support include:

Action Duchenne
Coalition Duchenne
Cure Duchenne
Duchenne Now
Duchenne Research Fund
Hope for Gus
Hope for Javier
Jain Foundation
Michael's Cause
Parent Project Muscular Dystrophy
Ryan's Quest
Zubin's Wish

About Duchenne Muscular DystrophyDuchenne muscular dystrophy is caused by a mutation in the dystrophin gene, resulting in progressive muscle weakness. The disease manifests itself first in weakened skeletal muscles and eventually results in cardiac and pulmonary impairment. Corticosteroids are the current standard of care treatment for DMD.  While this treatment delays disease progression by several years, their prolonged use is typically associated with side effects and the treatment does not alter the ultimate outcome of the disease.

About Halo TherapeuticsBased in Newton, Mass., Halo Therapeutics, LLC, is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for rare fibrotic diseases like Duchenne muscular dystrophy. Founded through a collaboration between patient advocacy organizations and industry veterans, the company is partnering with the clinical community and patients to transform therapeutic options and, by extension, lives. For more information, please visit www.halotherapeutics.com.Media Contact:Name:

Marc B. BlausteinCompany:

Halo Therapeutics, LLC617.431.7250mblaustein@halotherapeutics.com


'/>"/>

SOURCE Halo Therapeutics, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... financial results for the first quarter 2017 after the ... Company,s management team will host a corresponding conference call ... Investors interested in listening to the conference ... domestic callers or (703) 326-3030 for international callers, using ...
(Date:4/19/2017)... 2017  Sorrento Therapeutics, Inc. (NASDAQ: ... developing new treatments for cancer and other unmet ... previously announced underwritten public offering of 23,625,084 shares ... price of $2.00 per share, before deducting underwriting ... by Sorrento.  The net proceeds to Sorrento from ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... There is no better place in ... a special report in the May issue of Consumer Reports focused on heart health. ... for results achieved during and after coronary bypass and aortic valve replacement procedures. ...
(Date:4/24/2017)... ... April 24, 2017 , ... LG ... Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s national ... which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use kit ...
(Date:4/24/2017)... ... April 24, 2017 , ... As part of the ... to honor the victims of the Holocaust and Nazi persecution, Center for Medicine ... and Auschwitz on its CMATH Champions trip to Germany and Poland next week. , ...
(Date:4/24/2017)... ... 2017 , ... The California Dental Association Foundation’s two-day volunteer dental clinic, ... during the April 22-23 event at the San Mateo Event Center. , In ... care, CDA Cares educates the public and policymakers about the importance of good oral ...
(Date:4/24/2017)... ... April 24, 2017 , ... ALP Nutrition®, a company ... its popular products are now available for purchase on StackedNutrition.com, a popular website ... of premium natural ingredients in making all of its products. These ingredients come ...
Breaking Medicine News(10 mins):